A5019293930- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Immunodeficiency and Autoimmune Disorders
- Immune Cell Function and Interaction
- Immune cells in cancer
- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
- Pericarditis and Cardiac Tamponade
- Amoebic Infections and Treatments
- CAR-T cell therapy research
- Ubiquitin and proteasome pathways
- Intraperitoneal and Appendiceal Malignancies
- Acute Myeloid Leukemia Research
- Renal and related cancers
- Monoclonal and Polyclonal Antibodies Research
- Advanced Breast Cancer Therapies
- Viral-associated cancers and disorders
The University of Texas Southwestern Medical Center
2024
Ohio University
2023
The Ohio State University
2016-2019
National Student Clearinghouse Research Center
2018
Abstract Myeloid-derived suppressor cells (MDSC) are a heterogeneous group of immature myeloid that expand in tumor-bearing hosts response to soluble factors produced by tumor and stromal cells. MDSC expansion has been linked loss immune effector cell function reduced efficacy immune-based cancer therapies, highlighting the population as an attractive therapeutic target. Ibrutinib, irreversible inhibitor Bruton's tyrosine kinase (BTK) IL2-inducible T-cell (ITK), is clinical use for treatment...
Targeted inhibition of Bruton tyrosine kinase (BTK) with the irreversible inhibitor ibrutinib has improved outcomes for patients hematologic malignancies, including chronic lymphocytic leukemia (CLL). Here, we describe preclinical investigations ARQ 531, a potent, reversible BTK additional activity against Src family kinases and related to ERK signaling. We hypothesized that targeting would improve global signaling pathways, producing more robust responses. In vitro treatment patient CLL...
Nemtabrutinib is an orally bioavailable, reversible inhibitor of Bruton tyrosine kinase (BTK) and C481S mutant BTK. We evaluated the safety, pharmacology, antitumor activity nemtabrutinib in relapsed/refractory hematologic malignancies. Forty-eight patients with chronic lymphocytic leukemia (CLL), B-cell non-Hodgkin lymphoma (NHL), or Waldenström macroglobulinemia (WM), after ≥2 prior therapies were enrolled open-label, single-arm, phase I MK-1026-001 study (NCT03162536) to receive 5 75 mg...
Abstract Introduction: In order to address the issue of acquired resistance ibrutinib, we sought characterize Bruton agammaglobulinemia tyrosine kinase (BTK) inhibitor SNS-062 in preclinical models chronic lymphocytic leukemia (CLL). Methods: Primary CLL B cells were isolated from whole blood consented patients by ficoll density centrifugation and Rosette-Sep negative selection. Annexin V propidium iodide flow cytometry was used measure patient cell viability 7-AAD stromal co-culture. CD40...
7530 Background: BTK is an attractive target in CLL. Ibrutinib (IB), a first class irreversible inhibitor (BTKi), abrogates important survival signals CLL by proximally blocking multiple pathways. Despite IB’s ability to produce remissions patients, resistance can occur via mutation at its binding site. IB also inhibits ITK, limiting antibody dependent cytotoxicity (ADCC) and the efficacy of therapy. Here we demonstrate potential utility novel BTKi, GDC-0853, which does not rely upon C481...
Case Reports1 June 1953ACUTE SUPPURATIVE CHOLECYSTITIS, WITH RUPTURE OF GALL-BLADDER AND LIVER ABSCESS FORMATION, DURING ADMINISTRATION CORTISONESIDNEY REIFF, M.D.SIDNEY M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-38-6-1313 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptIt is now well established that intercurrent infections become worse...
<p>Supplementary Figure S1 shows mean (+SD) plasma concentrations of nemtabrutinib vs time following single (C1D1) oral doses MK-1026 (linear and semi-log plots) nM</p>
<div>Abstract<p>Nemtabrutinib is an orally bioavailable, reversible inhibitor of Bruton tyrosine kinase (BTK) and C481S mutant BTK. We evaluated the safety, pharmacology, antitumor activity nemtabrutinib in relapsed/refractory hematologic malignancies. Forty-eight patients with chronic lymphocytic leukemia (CLL), B-cell non–Hodgkin lymphoma (NHL), or Waldenström macroglobulinemia (WM), after ≥2 prior therapies were enrolled open-label, single-arm, phase I MK-1026-001 study...
<p>Supplementary Figure S1 shows mean (+SD) plasma concentrations of nemtabrutinib vs time following single (C1D1) oral doses MK-1026 (linear and semi-log plots) nM</p>
<div>Abstract<p>Nemtabrutinib is an orally bioavailable, reversible inhibitor of Bruton tyrosine kinase (BTK) and C481S mutant BTK. We evaluated the safety, pharmacology, antitumor activity nemtabrutinib in relapsed/refractory hematologic malignancies. Forty-eight patients with chronic lymphocytic leukemia (CLL), B-cell non–Hodgkin lymphoma (NHL), or Waldenström macroglobulinemia (WM), after ≥2 prior therapies were enrolled open-label, single-arm, phase I MK-1026-001 study...
Inhibition of immune checkpoint proteins is effective in adult cancers but has shown limited efficacy pediatric cancers. While factors regulating expression such as PD-L1 are well-documented cancers, their regulation poorly understood Here, we show that upregulated distinct subsets Wilms tumor, the most common kidney cancer. Specifically, chemotherapy-exposed tumor specimens exhibited higher levels expression, and chemotherapeutics childhood cancer cell lines
Abstract Background: B-cell receptor (BCR)-mediated signaling plays an important role in the pathogenesis of a subset diffuse large lymphoma (DLBCL). Despite major advances treatment, ~40% relapsed/refractory DLBCL patients still experience early treatment failure after initial response to chemotherapy. ARQ 531, reversible inhibitor BTK and BTK-C481S mutant, also potently suppresses BCR signaling. Here we demonstrate that 531 targets additional kinases multiple oncogenic pathways, this...
<p>methods</p>
<p>methods</p>
<p>Suppl Figure 1 with legend</p>
<p>Suppl Table 2 with legend</p>
<p>Suppl Table 1 with legend</p>